H.C. Wainwright lowered the firm’s price target on Moleculin Biotech (MBRX) to $8 from $45 and keeps a Buy rating on the shares. The firm adjusted its model to the effect of a 1-for-15 reverse stock split that took effect in March 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX: